Genmab A/S
GNMSFOTCHealthcare● Active
$249.45
$-21.15(-7.82%)
Market Cap$15.3B
P/E Ratio—
52W High$352
52W Low$198.51
Genmab A/S (GNMSF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GNMSF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.85B | $21.53B | $16.47B | $14.51B | $8.48B |
| Cost of Revenue | $0.32B | $0.98B | $0.23B | $0.00B | $0.00B |
| Gross Profit | $3.53B | $20.54B | $16.25B | $14.51B | $8.42B |
| Gross Margin %(computed) | 91.69% | 95.42% | 98.63% | 100.00% | 99.23% |
| Operating Expenses | |||||
| R&D Expenses | $1.61B | $9.75B | $7.63B | $5.56B | $4.18B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $2.24B | $13.84B | $10.93B | $8.24B | $5.46B |
| Operating Income | $1.29B | $6.98B | $5.32B | $6.27B | $2.95B |
| Operating Margin %(computed) | 33.60% | 32.43% | 32.30% | 43.21% | 34.81% |
| Interest Income | $0.14B | $0.99B | $0.94B | $0.32B | $0.20B |
| Interest Expense | $0.06B | $0.12B | $0.03B | $0.02B | $0.01B |
| Income Before Tax | $1.25B | $9.16B | $5.64B | $6.95B | $3.92B |
| Income Tax Expense | $0.25B | $1.32B | $1.28B | $1.49B | $0.96B |
| Net Income | $1.00B | $7.84B | $4.35B | $5.45B | $2.96B |
| Net Margin %(computed) | 25.89% | 36.44% | 26.42% | 37.59% | 34.86% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $16.04 | $122.21 | $66.64 | $83.38 | $46.00 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.07B | 0.07B | 0.07B |
| EBITDA | $1.37B | $9.70B | $5.99B | $7.33B | $3.15B |
| EBITDA Margin %(computed) | 35.51% | 45.05% | 36.37% | 50.52% | 37.10% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Genmab A/S data
About Genmab A/S (GNMSF) Income Statement
Genmab A/S (GNMSF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GNMSF reported revenue of $3.85B, gross profit of $3.53B (gross margin 91.69%), and net income of $1.00B — a net profit margin of 25.89%.
Frequently asked questions
GNMSF · 4 questionsGenmab A/S (GNMSF) reported revenue of $3.85B for 2025, down 82.1% year-over-year.
GNMSF revenueGNMSF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08